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A BAc transgene expressing 
Human cftR under control of its 
Regulatory elements Rescues cftr 
Knockout Mice
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Austin e. Gillen6,9, Michael J. Mutolo6, George Kotzamanis7, Jürgen Bosch3,8, Ann Harris5, 
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Small-molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR) biology 
show promise in the treatment of cystic fibrosis (CF). A Cftr knockout (Cftr KO) mouse expressing 
mutants of human CFTR would advance in vivo testing of new modulators. A bacterial artificial 
chromosome (BAC) carrying the complete hCFTR gene including regulatory elements within 40.1 kb 
of DNA 5′ and 25 kb of DNA 3′ to the gene was used to generate founder mice expressing hcftR. 
Whole genome sequencing indicated a single integration site on mouse chromosome 8 (8qB2) with ~6 
gene copies. hcftR+ offspring were bred to murine Cftr KO mice, producing hCFTR+/mcftr− (H+/
m−) mice, which had normal survival, growth and goblet cell function as compared to wild-type 
(WT) mice. Expression studies showed hCFTR protein and transcripts in tissues typically expressing 
mCftr. Functionally, nasal potential difference and large intestinal short-circuit (Isc) responses to cAMP 
stimulation were similar in magnitude to WT mice, whereas small intestinal cAMP Δisc responses were 
reduced. A BAc transgenic mouse with functional hcftR under control of its regulatory elements has 
been developed to enable the generation of mouse models of hCFTR mutations by gene editing for in 
vivo testing of new cf therapies.
High throughput screening and lead optimization have led to the successful introduction of FDA-approved small 
molecular compounds that modulate the biology of the cystic fibrosis transmembrane conductance regulator 
(CFTR) for the treatment of cystic fibrosis (CF) patients. Greatest strides have been made with “potentiator” com-
pounds, e.g., Ivacaftor®, that increase CFTR channel gating, likely through direct binding to the mutant protein1. 
CF patients that benefit the most have type III mutations of at least one allele where CFTR protein is made in suffi-
cient amounts and traffics to the plasma membrane but has defective channel gating, e.g., G551D. Some with type 
IV mutations, i.e., defective channel conduction (e.g., R117H) also benefit from potentiator treatment. Less effi-
cacious have been the “corrector” compounds, e.g. Lumacaftor®, that function to chaperone the mutant protein 
during cellular processing. Correctors are targeted at CFTR mutations, including ΔF508 which constitutes ~85% 
of CFTR mutant alleles1 (https://www.cff.org/Research/Developing-New-Treatments/CFTR-Modulator-Types/). 
The success of these compounds have spawned great interest in the development of the next generation of CFTR 
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modulators, including “amplifiers” that increase the CFTR expression, and other therapeutic modalities such as 
targeting sodium channel activity or mucus secretion. Therefore, the development of mouse models expressing 
human CFTR (hCFTR) and relevant mutations in the absence of endogenous murine Cftr (mCftr) may be useful 
for pre-clinical in vivo trials to assess new modulator compounds.
Beyond heterologous expression systems, stable hCFTR expression in murine tissues has previously been 
accomplished using a yeast artificial chromosome (YAC) to rescue mCftr knockout mice2,3. A 310 kb YAC 
genomic construct containing the entire coding region of hCFTR and ~70 kb upstream of the 5′ end of exon 1 was 
used in pronuclear injection to generate transgenic mice expressing hCFTR. The two clones of YAC hCFTR mice 
were bred to the cftrtm1CAM null allele mice to complement the loss of endogenous mCftr2. Both clones increased 
survival and showed functional expression of hCFTR in intestinal segments, with one clone showing wild-type 
responses to cAMP stimulation of anion secretion and the other showing lower responses. Only one clone cor-
rected cAMP-stimulated chloride secretion in the mCftr-null trachea. Overall, the YAC hCFTR matched mCftr 
tissue-specific expression in intestines and salivary glands, and low expression in the lung and pancreas. At the 
time, molecular studies of CFTR expression identified some DNase I hypersensitive (DHS) sites responsible for 
tissue-specific expression and tissue-specific enhancer activity in the hCFTR locus, which were also evident in 
the YAC hCFTR4,5. Work that is more recent identified multiple tissue specific DHS containing critical regulatory 
elements both 5′ to the promoter and 3′ to the end of the gene in airway epithelial cells6,7 and within introns in 
intestinal epithelial cells8. Based on the earlier studies and interest in the development of a gene therapy construct, 
a 250.3 kb bacterial artificial chromosome (BAC) transgene was engineered containing the entire coding region of 
hCFTR, 40.1 kb of DNA 5′ and 25 kb of DNA 3′ to the gene9. Though this BAC lacks the topologically associating 
domain (TAD) boundaries for CFTR (at −80.1 kb and +48.9 kb10–12) it contains the majority of key tissue-specific 
control elements for the locus. In the present study, this construct was used to develop a BAC transgenic mouse 
model expressing hCFTR by its endogenous regulatory elements with the purpose of introducing different CF 
mutations by gene editing and subsequent in vivo testing of CFTR modulators and other therapeutic modalities 
for the treatment of cystic fibrosis.
Results
BAc hcftR transgenic mice. Nine founders were produced from pronuclear injection (4 females, 5 males). 
Of the nine, 3 male founders produced pups that were transgene positive. Jejunal tissue from the offspring were 
tested for intact hCFTR mRNA using a TaqMan® (Life Sciences) assay directed at the exon 27–28 boundary of 
hCFTR. Only the offspring from one male founder was strongly positive for hCFTR mRNA at this site. Offspring 
from the hCFTR founder were bred into mCftr KO mice to generate hCFTR+/mCftr− (H+/m−) mice.
integration site and copy number of the hcftR BAc. DNA from an hCFTR+ mouse was isolated and 
whole genome sequencing was completed. A single integration site was identified on mouse chromosome 8 in 
region 8qB2 (Fig. 1a). Using UCSC Genome Browser®, we observed no promoters, enhancers or heterochromatin 
in this region that would significantly impact expression of the hCFTR transgene. The closest promoter for a gene 
is over 400 kb away from the integration site. The single insertion site was verified with a fluorescently labeled 
BAC in mouse embryonic stem cells from an hCFTR+ mouse (Fig. 1b). To determine the number of copies of the 
hCFTR BAC integrated at this single site, qPCR was completed at three sites within the hCFTR BAC sequence. 
Compared to genomic human DNA (2 copies), there was an average of 5.6, 6.8 and 6.2 copies 5′, within hCFTR 
and 3′ of the gene respectively (Fig. 1c).
Survivability and growth of hCFTR mice. Post-weaning cohorts of WT, H+/m− and hCFTR−/mCftr− 
(H−/m−) were provided standard mouse chow and regular drinking water to determine survivability. Body 
weight and length were also measured. As shown in Fig. 1d, all but one of the WT mice and all H+/m− mice 
survived the post-weaning period until terminated at 40 days of age. In contrast, H−/m− mice had reduced 
survivability (~40%) during the same time period. Of the surviving mice (Fig. 1e), both WT and H+/m− mice 
gained body weight at a rate of 0.50 g/day which compares favorably to previous reports of WT mouse growth 
rates (0.53 g/day) of mice during the period of 15 to 30 days of age13. As expected13, H−/m− mice during this 
time period grew at a slower rate (0.13 g/day). As shown in Fig. 1f, body length of the mice also reflected differ-
ences in growth with nearly equivalent body length between WT C57Bl/6 (Jackson Labs), WT from the colony 
and H+/m− mice, with all significantly exceeding the body length of H−/m− mice.
Tissue-specific hCFTR mRNA expression. Using qRT-PCR, the tissue-specific expression of the hCFTR 
transgene was screened in several tissues of H+/m− mice. Figure 2a,b shows strong expression in intestinal seg-
ments of the small and large bowel. High expression was also noted in the submandibular salivary glands, spleen 
and the testes. hCFTR was expressed in other tissues affected by CF disease including the airways (nasal, trachea, 
lung), liver and pancreas. Little or no expression was apparent in the uterus. The enamel organ of the incisor teeth 
was not tested but H+/m− mice exhibited white central incisors with chipping of the tooth edges on the lower 
incisor pair. This is an overt phenotypic characteristic of Cftr KO mice as a result of reduced mineralization and 
low Fe levels in the enamel of the hypsodont incisors14.
hcftR protein expression in H+/m− in intestine and airways. Immunoblots for hCFTR in the mCftr- 
background in isolated small intestinal crypts were compared to CHO cells expressing recombinant human CFTR (a 
kind gift from T.C. Hwang, University of Missouri). N-glycanase treatment of the cells enabled assessment of the gly-
cosylation status of hCFTR15. As shown in Fig. 2c (lane 2), recombinant hCFTR expressed in CHO cells migrated pri-
marily as the fully glycosylated band C and a small amount of core glycosylated protein (band B), migrating at ~175 kD 
and ~150 kD, respectively. After treatment with N-glycanase, the recombinant hCFTR migrated primarily as band A  
(lane 3). Immunoblot analysis of hCFTR in freshly-isolated intestinal crypts from three H+/m− mice showed a band 
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migrating near the region of band A (~135 kD) as indexed by the N-glycanase treated recombinant CFTR  (lanes 4-6). 
Murine Cftr showed band C staining (lane 7) whereas a banding pattern for Cftr was not detected in isolates from Cftr 
KO intestinal crypts  (lane 8), indicating the specificity of the anti-CFTR 3g11 antibody. All mouse intestinal isolates 
also showed a non-specific band migrating at ~125 kD. N-glycanase treatment of H+/m− intestinal isolates did not 
affect the migration pattern of the hCFTR-specific band (data not shown). CFTR protein expression was also assessed 
in lung epithelial cells using imaging flow cytometry. CFTR presence is noted on the apical ciliated end of the lung 
epithelial cells from WT and H+/m− but not from H−/m− mice (Fig. 2d). A similar staining pattern was observed in 
human bronchial epithelial cells (Fig. 2e). While there is some nonspecific staining in H−/m− cells, the number and 
intensity of CFTR staining in WT and H+/m− cells is significantly different than in H−/m− cells (Fig. 2f,g).
Figure 1. Rescue of mCftr KO mouse with hCFTR BAC transgene. (a) Integration locus: hCFTR BAC transgene 
inserted into a single insertion site on mouse chromosome 8qB2 (indicated by the red line). Region is expanded 
to show the exact site in chromosome 8 region with arrows indicating directionality, green bars indicating BAC 
backbone and red indicating hCFTR (not to scale). (b) Fluorescence in situ hybridization using a fluorescently 
labeled BAC (red) and a distal chromosome 8-labeled probe (green) on embryonic stem cells from a H+/m− 
mouse embryo. (c) qPCR analysis of hCFTR copy number to three regions of the hCFTR BAC (5′ of hCFTR, 
intron 14 and 3′ of hCFTR) in H+/m− mice (black circles) and human (gray circles) control DNA samples. 
(d) Survivability of H/m genotypes. (n ≥ 14 mice/genotype). (e) Body weight of H/m genotypes during first 40 
days of age (n = 20 per group with equal numbers of each sex). Bars indicate standard deviation. (f) Body length 
comparison of H/m genotypes by sex (n ≥ 6 per group). Inset, comparison of body length by genotype, inclusive of 
a non-colony B57BL/J wild-type mouse (WT*). a,bMeans with the same letters are not significantly different.
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Figure 2. Tissue-specific expression. (a) Agarose gel displaying mRNA tissue specific expression of hCFTR 
in H+/m− mice. (b) qPCR results displaying relative tissue-specific mRNA expression of hCFTR in H+/
m− mice. (n = 3–6 mice). (c) Immunoblot analysis of recombinant hCFTR expressed in CHO cells, hCFTR 
in freshly isolated crypts from three H+/m− mice and mCftr WT and KO intestine. Lane 1, untransfected 
CHO cells; Lane 2, recombinant hCFTR transfected CHO cells with sham treatment; Lane 3, recombinant 
hCFTR CHO cells treated with N-glycanase; Lane 4–6, H+/m− jejuna from 3 H+/m− mice; Lane 7, freshly-
isolated crypts from a WT mouse and Lane 8, freshly-isolated crypts from a Cftr KO jejunum. Arrows indicate 
molecular mass markers. Lower panel, GAPDH as loading control. Representative of 9 H+/m− mice. (d) 
Imaging flow cytometry analysis of mouse tracheal epithelial cells stained with anti-CFTR RB7865 and the 
nuclear stain DRAQ5. Representative cells from WT, H+/m− and H−/m− murine cells in brightfield (BF), 
stained for DRAQ5 (red) and CFTR (green), and merged images. The top panel of images represents WT cells 
stained with the pre-immune isotype control of RB7865. Second through fourth panels represent WT, H+/m− 
and H−/m− airway cells, respectively. (e) Representative human bronchial epithelial cells. Note the localization 
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intestinal morphology of the hcftR mice. Intestinal pathology is the major manifestation of cystic 
fibrosis in Cftr KO mouse models. Intestinal pathogenesis involves mucoviscidosis that includes goblet cell hyper-
plasia, increased goblet cell volume, viscid mucus and mucus plugging of crypts. Another morphological differ-
ence of Cftr KO mouse intestine is increased length of the crypt-villus axis resulting from increased epithelial 
proliferation and, possibly, decreased apoptosis16,17. Histological sections of the jejunum and proximal colon were 
compared among WT, H+/m− and H−/m− mice. As shown Fig. 3a,b, the appearance of the jejunum and the 
proximal colon was indistinguishable between WT and H+/m− mice. In contrast, the H−/m− jejunum showed 
overt increases in the length of the crypt-villus axis (see quantification in Fig. 3d). Furthermore, despite the 
mitigating effect of osmotic laxative treatment18, both the jejunum and proximal colon of H−/m− mice showed 
evidence of mucoviscidosis including mucus plugging of crypts mucus, trapping of Paneth cell granules and 
enlarged goblet cells, as shown in Fig. 3c and inset.
Goblet cell exocytosis in the hcftR intestine. Mucus anchoring, whereby expelled mucus from Cftr KO 
goblet cells remains attached at the goblet cell theca, is a contributing factor to mucoviscidosis and intestinal obstruc-
tion by expanding the surface area for mucus attachment to the epithelial surface19. Videomicroscopy was used to 
evaluate goblet cell exocytosis during carbachol stimulation in cultured distal jejunal organoids from sex-matched 
WT, H+/− and H−/m− littermate mice. As shown in Fig. 4a, goblet cell exocytosis induced by carbachol treatment in 
organoids from WT mice resulted in normal degranulation as indicated by immediate dissolution of released granules 
and “cupping” at the apical theca of the partially degranulated goblet cell. Similarly, goblet cells in H+/m− organoids 
underwent rapid and apparently normal exocytosis (Fig. 4b). In contrast, exocytosis in H−/m− goblet cells was slower 
and resulted in the formation of anchored mucus plugs extending into the intestinal lumen (Fig. 4c).
Functional activity of hCFTR in murine epithelia. Activation of CFTR and Cl− secretion into the 
nasal lumen causes hyperpolarization of the nasal epithelium. As shown in Fig. 5a, in vivo measurements of 
cAMP-stimulated nasal potential difference (ΔNPD)20 showed similar magnitude of responses between WT 
and H+/m− mice; whereas H−/m− mice exhibited a ΔNPD that was not significantly different from zero 
(1 ± 0.64 mV).
Intestinal sections were mounted in Ussing chambers for the measurement of short-circuit current (Isc), as 
previously described21. As shown in Fig. 5b, H+/m− jejunal sections had a robust Isc response to intracellular 
cAMP stimulation within 5 min, which was ~45–50% inhibited within 15 min by CFTRinh-172. In contrast, the 
H−/m− jejunum had virtually no response to cAMP stimulation or treatment with CFTRinh-172. A comparison 
of the basal and stimulated electrophysiological properties of the jejunum from WT, H+/m− and H−/m− mice 
are shown in Table 1. Under basal conditions, WT jejuna have a significantly greater basal Isc as compared to the 
H+/m−and H−/m− jejuna, which were not statistically different from each other. Transepithelial conductance 
(Gt), primarily a measure of paracellular ion permeability of the small bowel22, was not different among the gen-
otypes. Following cAMP stimulation using a forskolin/IBMX cocktail, the Isc increased significantly in all geno-
types except the H−/m− intestine. However, the cAMP-stimulated ΔIsc was greater in WT as compared the H+/
m− intestine (shown graphically in Fig. 5c). No significant differences in Gt between genotypes were detected 
after cAMP stimulation.
comparison of isc between H+/m− and WT mice in different intestinal segments. Based on 
finding a lower cAMP ΔIsc response in H+/m− jejunum as compared to that in WT mice, we investigated the 
cAMP- and Cftrinh-172-induced Isc responses in different intestinal segments between sex-matched H+/m− and 
WT littermate mice. As shown in Fig. 6a, the cAMP-induced Isc in H+/m− mice was significantly less in the 
duodenum and jejunum, as compared to that in the WT mice. However, the cAMP-induced Isc in the large bowel 
(proximal and distal colon) was comparable between the two genotypes and did not attain a statistically signif-
icant difference. As shown in Fig. 6b, inhibition of the cAMP-stimulated Isc using CFTRinh-172 was greater in 
the WT small intestine, but owing to the greater cAMP-induced Isc, the percent inhibition by CFTRinh-172 was 
similar between H+/m− and WT intestine, respectively (Duodenum %ΔIsc = −45.3 ± 8.2 vs. −38.5 ± 4.2, ns; 
Jejunum %ΔIsc = −51.6 ± 5.4 vs. −43.5.6 ± 5.0, ns). In the large intestine, inhibition of the cAMP-stimulated Isc 
by CFTRinh-172 was significantly greater in the H+/m− proximal colon and similar in the distal colon, as com-
pared to WT colon.
Bicarbonate transport by hcftR intestinal epithelium. CFTR is permeable to the anions Cl− and 
HCO3− at a ratio of approximately 4:123. To assess HCO3− transport by hCFTR, jejunal and proximal colonic 
sections from H+/m−, WT and H−/m− mice were compared for Isc responses to a forskolin/IBMX cocktail 
while bathed in Cl− free KBR. As shown in Fig. 6c, cAMP stimulation significantly increased the Isc in the H+/
m− jejunum relative to that in the H−/m− jejunum by ~30 µA/cm², which equates to a secretory HCO3− flux of 
~1 µeq/cm²·hr. A greater ΔIsc response was exhibited by the WT jejunum which exceeded the Isc response by the 
H−/m− jejunum by ~60 µA/cm², equating to a secretory HCO3− flux of ~2 µeq/cm²·hr. Subsequent treatment 
of the CFTR signal towards the cilia in both panels. (f) Population quantification of all selected and analyzed 
mouse tracheal cells displaying the frequency of a cell with each intensity for the antibody with WT pre-bleed 
(red), WT (green), H+/m− (blue) and H−/m− (grey). (g) Overall CFTR intensity for each population. The 
mean and 95% confidence level is represented in the shaded box, whiskers indicate minimum and maximum in 
the dataset. Numbers below each sample set represent the final amount of cells used for analysis. *Significantly 
different from each other.
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with CFTRinh-172 had a negligible inhibitory effect on the HCO3−dependent Isc in the three genotypes. A similar 
pattern to cAMP stimulation and CFTR inhibition emerged in studies of the proximal colon (Fig. 6d), although 
the H+/m− Cl− free ΔIsc response to cAMP stimulation did not attain statistical significance in comparison to 
that of the H−/m− proximal colon. In contrast, the ΔIsc response to forskolin/IBMX was more robust in the WT 
colon and significantly exceeded the response by the H+/m− colon, yielding a calculated HCO3− flux of ~3.5 
µeq/cm²·hr. Subsequent treatment with CFTRinh-172 had little effect on the ΔIsc response in the three genotypes.
Discussion
The goal of this research was to develop a BAC transgenic mouse model expressing genomic human CFTR under 
control of its native regulatory elements. The value of this model is the possibility of using CRISPR/Cas9 gene 
editing to generate H+/m− mice expressing common CFTR mutations at the same integration site. Thus, CFTR 
modulators and other treatments can be compared in a consistent genetic background in vivo in mice.
Two early manifestations of CF disease are bowel obstruction and growth retardation. Intestinal obstructive 
disease in CF includes a spectrum from meconium ileus/meconium stasis at birth to obstructive syndromes 
in adult CF patients24,25. Growth abnormalities include reduced height and weight for age and percentage of 
ideal body weight26. Both bowel obstruction and growth retardation are recapitulated in CF mouse models14,27,28. 
Further, studies of enterocyte-specific knockout and knock-in of mCftr indicate that non-epithelial tissues also 
contribute to both growth retardation and bowel obstruction29. The lack of bowel obstruction and growth retar-
dation in H+/m− mice is evidence of regulated hCFTR expression in the BAC transgenic model. One apparent 
exception is the enamel organ because the phenotype of white teeth was not corrected by  the hCFTR trans-
gene. However, rodents have continuously growing hypsodont incisors, whereas all dentition in humans are 
slow-growing brachydont teeth. Brachydont molars in mice require little or no Cftr activity for normal minerali-
zation14. Fortuitously, the white incisor teeth phenotype provides an overt indicator of a mCftr-null background 
in the hCFTR mice.
Figure 3. Intestinal morphology. Representative hematoxylin/eosin-stained sections of the jejunum and 
proximal colon from (a) WT (H+/m+), (b) H+/m− and (c) H−/m− mice (200X mag). In the H−/m− 
sections, mucus-encased Paneth cell granules are shown with black arrow and inset; enlarged goblet cells are 
indicated by yellow arrowheads; and crypt plugging is indicated by white arrows. Representative of n = 4 mice 
of each genotype. (d) Villus and crypt lengths in H/m genotypes, n = 5 mice/genotype. a,bMeans with the same 
letters are not significantly different.
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Consistent with regulated hCFTR expression, screening for hCFTR mRNA transcripts showed expression in 
various tissues known to express endogenous mCftr. Strongest expression was in the salivary glands, intestinal 
tract and testes, a finding consistent with human studies30–32. Based on our functional tests, the hCFTR mouse 
appeared to have an increasing proximal-distal gradient of CFTR activity whereas in situ hybridization studies 
in human show a decreasing proximal-distal intestinal gradient of CFTR expression31. hCFTR expression was 
present in the airways but at lower levels, as reported in human7. Most mRNA was collected from whole organ 
homogenates and not epithelial isolations, thus in CF-affected organs like pancreas and liver32, low expression is 
likely due to the dilution of the ductal hCFTR mRNA by RNA from the organ parenchyma.
The CFTR immunoblot of the H+/m− jejunal lysates indicated that hCFTR protein in the H+/m− intestine 
appears to migrate as band A, indicating that hCFTR is unglycosylated. This observation is supported by inability 
of N-glycanase to affect the hCFTR band migration and specificity of the antibody by lack of the band in the Cftr 
KO mouse intestine. Since six copies of the BAC transgene were detected at the integration site, it is possible that 
sufficient amounts of unprocessed hCFTR localized to the apical membrane to provide the robust functional 
activity shown in the electrophysiological experiments. In support, previous studies have shown that overexpres-
sion of the poorly glycosylated ΔF508 CFTR in cell systems yields cAMP-stimulated halide efflux33. Sequencing at 
Figure 4. Effect of hCFTR on goblet cell degranulation in intestinal organoids. (a) WT goblet cell (white arrow) 
in distal jejunum undergoes rapid exocytosis from the apical pole of the theca with dissolution of granules. L, 
lumen of organoid. Black arrow, denotes apical (luminal) membrane. (b) H+/m− goblet cell (white arrow) also 
undergoes rapid, normal exocytosis. L, lumen of organoid. Black arrow, denotes apical (luminal) membrane. (c) 
H−/m− goblet cell (white arrow) undergoes slow exocytosis with mucus anchoring to goblet cell theca (white 
chevron). Black arrow, denotes apical (luminal) membrane. Representative of 3 experiments (Mag. 600x).
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both ends of the hCFTR insertion site indicated that the integration site was adjacent to the backbone of the BAC 
on both sides, but it is possible that most of the hCFTR copies rearranged to yield either misfolded protein or a 
configuration that interfered with the glycosylation process. Understanding the changes in glycosylation pattern 
of the hCFTR will likely require complete sequencing of the integration site.
Pathological features of intestinal CF that are modeled by Cftr KO mice include mucoviscidosis and a hyper-
proliferative intestinal mucosa17,27,34. Morphological assessment of the H+/m− jejunum and proximal colon did 
not reveal overt differences from tissue sections from WT mice. As expected, H−/m− small intestine showed 
evidence of mucoviscidosis, goblet cell dysfunction and increased length of the crypt-villus axis. Thus, expression 
Figure 5. Functional activity of hCFTR in nasal and intestinal mucosa. (a) Change in nasal potential difference 
(NPD) after forskolin stimulation in a chloride-free solution (n ≥ 6 mice/genotype). (b) Short-circuit current 
(Isc) responses of H+/m− and H−/m− jejuna to forskolin (10 µM)/IBMX (100 µM) stimulation and subsequent 
treatment with CFTRinh-172 (10 µM), n = 10 and 4 mice, respectively. Only two of four H−/m− mice were 
treated with CFTRinh-172. *Significantly different from time 0. #Significantly different from time 20 min. (c) 
Cumulative data for forskolin/IBMX ΔIsc responses of WT (n = 3 mice), H+/m− (n = 10 mice, from Fig. 4D) 
and H−/m− (n = 3 mice) jejunal sections. a,b,cMeans with the same letters are not significantly different.
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of the hCFTR transgene in the mCftr- mouse corrects two disparate manifestations of intestinal CF that have 
been associated with obstructive bowel disease and an increased risk of gastrointestinal cancer in CF patients27,34.
Cyclic AMP stimulation of anion secretion by the hCFTR transgene was observed in the mCftr-null background in 
both airway and intestine. Measurements of nasal potential difference in H+/m− mice were not significantly different 
from WT mice suggesting substantial hCFTR function in the airway. Further studies of the intestine showed evidence 
of bicarbonate transport and sensitivity to CFTRinh-172. Measurements of small intestine Isc in H+/m− mice demon-
strated a smaller response to cAMP stimulation in comparison to mice expressing endogenous mCftr. With respect 
to the small intestinal responses, the H+/m− ΔIsc upon cAMP stimulation (~60–80 µA/cm²) is within the range of 
cAMP-stimulated ΔIsc previously reported for control human small intestine (~25–90 µA/cm²)35–38, although greater 
responses have since been observed39. Importantly, the cAMP-stimulated ΔIsc by the H+/m− colon (~160–170 µA/cm²), 
WT H+/m− H−/m−
Isc Gt Isc Gt Isc Gt
Genotype
Basal
−40.9* 38.5 −15.1 40.3 −14.3 34.0
±6.1 ±4.0 ±4.8 ±2.6 ±6.5 ±3.5
cAMP
−252.1+,* 33.9 −99.9+ 40.8 −17.0* 35.5
±20.9 ±5.4 ±9.8 ±2.8 ±8.3 ±4.7
(6) (10) (3)
Table 1. Electrophysiology of proximal jejunum. Isc, short-circuit current (µA/cm²). Gt, transepithelial 
conductance (mS/cm²). *P < 0.05 vs. H+/m−; +P < 0.05 vs. Basal. Parentheses = number of mice.
Figure 6. Comparison of function between hCFTR and mCftr in different intestinal segments and bicarbonate 
(HCO3−) transport by hCFTR in mouse jejunum and colon. (a) Comparison of change in short-circuit 
current (ΔIsc) to cAMP stimulation by forskolin (10 µM)/IBMX (100 µM) in duodenum (Duod), jejunum 
(Jej), proximal colon (PC) and distal colon (DC) mucosae between WT and H+/m− sex-matched littermate 
mice (n = 6 mice of each genotype). *Significantly less than WT. (b) Effect of CFTRinh-172 on ΔIsc after 20-
min forskolin/IBMX treatment in different intestinal segments comparing H+/m− and WT sex-matched 
littermate mice (n = 6 mice of each genotype). *Significantly less than WT. #Significantly greater than WT. (c,d) 
ΔIsc response to forskolin/IBMX and subsequent treatment with CFTRinh-172 superfused with Cl–free KBR 
solution in jejunum and proximal colon, respectively, n = 6 WT and H+/m− mice; n = 3 H−/m− sex-matched 
littermate mice. a,b,cMeans with the same letters are not significantly different.
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as well as CFTRinh-172 inhibition, were similar in magnitude to the endogenous mCftr colonic responses and matched 
well with previously reported cAMP-stimulated ΔIsc of control human colon (~85–145 µA/cm²)36,40. Overall, electro-
physiological studies of H+/m− intestine show that the Isc responses are perhaps more consistent with human than 
murine intestine and that the colonic mucosa may provide the best signal-to-noise ratio for discerning Isc differences 
between CFTR modulators.
One limitation with the hCFTR model is the integration of multiple copies of the BAC at the single integration 
site. The integration of multiple copies arranged as a concatemer is common in microinjected DNA including 
BACs41,42. Our data suggest that there are six copies of hCFTR at this single site on mouse chromosome 8. Using 
traditional gene editing methods, inserting human CFTR mutations into these multiple copies of hCFTR may 
prove very difficult. However, utilizing CRISPR/Cas9 this feat may now be achieved with several reports citing 
gene editing of multiple genes at one time at high frequencies43–45. Future experiments to insert common human 
CFTR mutations in this model using CRISPR/Cas9 are necessary to determine the level of difficulty for editing 
the six hCFTR copies in this model.
A BAC transgenic mouse expressing hCFTR and its major regulatory elements has been developed and shows 
robust CFTR function in the airway and intestinal mucosa. The morphological and functional rescue by the BAC 
transgene in Cftr KO mice provides evidence of sufficient hCFTR activity at the apical membrane of CF-relevant 
epithelia. Thus, the opportunity presents itself to create mouse models expressing CF-causing mutations by gene 
editing methods. The functional activity of hCFTR in the BAC transgenic mouse suggests that introduction of 
disease-causing mutations will provide animal models useful for in vivo screening of CFTR potentiators such as 
VX-770. On the other hand, the response to CFTR processing correctors such as VX-890 may be more difficult 
to interpret because of the increased background of poorly processed hCFTR. An alternate scenario is that the 
sensitivity to identify processing correctors will be improved by greater availability of immature mutant hCFTR. 
Investigation of mutant hCFTR expression in the BAC transgenic mouse will likely increase our understanding of 
the biology behind CFTR processing. Overall, the generation of BAC transgenic mice carrying medically relevant 
hCFTR mutations is the next step in providing pre-clinical models for in vivo testing of CFTR modulators and 
other therapies for CF disease.
Methods
Mice. To generate hCFTR transgenic mice, a 250.3 kb BAC DNA fragment containing the entire coding 
sequence of hCFTR with its 27 exons, 40.1 kb of DNA 5′ and 25 kb of DNA 3′ to the gene was linearized using 
a Not1 digest of CFTR1,2,3OE BAC and microinjected into the male pronuclei of C57/BJ zygotes (Victor Lin, 
Precision Targeting, Inc., Tenafly, NJ). hCFTR founder mice were identified by PCR of genomic DNA using the 
following primers46: BAC123s-gDNA-5′ set (Exon/Intron 1): 5′-AGCGCCCGAGAGACCATGCA-3′/5′-CGAAG 
CTCGGTTGGCCACCTT-3′; BAC123s-gDNA-Mid set (Intron 10): 5′-GGGGGCCATGGGACTCACTGA-
3′/5′-TGCCACCAGCCTTACCGCTC-3′; and BAC123s-gDNA-3′ set (Intron 20): 5′-CACCGGCATTCCC 
CAATGAGACAG-3′/5′-TGCATGGAGCATTGCACAGCTGTTA-3′. hCFTR founders were outbred to Black 
Swiss (Charles River) mice and offspring were tested for expression of the hCFTR to assess germ-line transmis-
sion. The integrity of the transgene mRNA from the offspring of founders was probed using a TaqMan® assay 
(Life Sciences) designed to cross the exon 27–28 boundary near the C-terminus of hCFTR. Founder offspring 
expressing the BAC transgene were bred to mice with gene targeted disruptions of the murine homolog of Cftr 
[abcc7, Cftr knock-out (KO)]27 to generate mice that were positive for hCFTR and mcftr−/− (H+/m−) or neg-
ative for hCFTR and mcftr−/− (H−/m−). Survival, growth, histopathology or electrophysiological parameters 
were not different in mice expressing mcftr (mcftr+/+ or mcftr+/−) and that were either positive or negative for 
hCFTR, so these groups were combined as wild-type (WT). Genotypes were identified by PCR analysis of tail-
snip DNA as previously described47. All mice were maintained ad libitum on standard laboratory chow (Formulab 
5008, Rodent Chow; Ralston Purina) and distilled water in survival/growth experiments or distilled water con-
taining Colyte® (Schwartz Pharma) laxative to prevent intestinal obstruction in the H−/m− mice47. Mice were 
housed individually in a temperature- and light-controlled room (22–26 °C; 12-hour light: 12-hour dark cycle) 
in the Association for Assessment and Accreditation of Laboratory Animal Care-accredited animal facility at the 
Dalton Cardiovascular Research Center, University of Missouri. Mouse experiments were performed in accord-
ance with guidelines outlined in “Guide for the Care and Use of Laboratory Animals” prepared by the National 
Academy of Sciences and published by the National Institutes of Health and with approval from the University 
of Missouri Animal Care and Use Committee as well as the Case Western Reserve University Animal Care and 
Use Committee.
Histology. Jejunal sections were fixed in 10% neutral buffered formalin, dehydrated, and embedded in paraf-
fin. Samples were stained with hematoxylin and eosin and observed using light microscopy. For measurements of 
crypt and villus length, samples from five mice per genotype were scanned via a Leica SCN400 slide scanner and 
images were analyzed via VisiomorphDP software (Visiopharm).
immunoblot analysis. Freshly isolated murine jejunal crypts, CHO cells transfected with human CFTR 
(gift of T.-C. Hwang, University of Missouri) and non-transfected CHO cells were suspended in ice-cold PBS 
or RIPA containing Halt™ Protease inhibitor (ThermoFisher) and lysed at 4 °C by supersonication. Samples 
were centrifuged at 13, 000 rpm for 12 min at 4 °C. In some cases, supernatant was treated with PNGase F (New 
England BioLabs) for four hrs. at 37 °C then loaded on SDS-PAGE gels for electrophoresis, membrane transfer 
and immunoblotting. Anti-Cftr 3g11 (1:500 dilution, provided by CFTR Folding Consortium) was used as pri-
mary antibody. Secondary antibody was goat pAb to rat IgG (1: 2000 dilution, abcam, ab7097). Anti-GAPDH 
(1:2000 dilution, abcam, ab9485) was used as loading control and secondary antibody was goat pAb to rabbit IgG 
(1:2000 dilution, abcam, ab6721).
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Reverse transcription and quantitative PCR array (qRT-PCR). Tissue samples (duodenum, jejunum, 
ileum, cecum, proximal colon, distal colon, nasal mucosa, trachea, lung, spleen, heart, testes, uterus, liver, pan-
creas, salivary gland and kidney) were stored in RNA Later (−80 °C) until processing. Tissues were homogenized 
and total RNA extraction was performed using RNeasy Plus (according to the manufacturer’s protocol, Qiagen). 
Isolated RNA was reverse transcribed with Superscript III First Strand Synthesis Kit (Invitrogen) using oligo dT 
according to the manufacturer’s protocol. cDNA was used with individual TaqMan® Gene Expression Assays 
(ThermoFisher), according to the manufacturer’s protocol, for the exon 27–28 boundary near the C-terminus of 
hCFTR (Assay ID Hs01565549_m1) and three housekeeping genes β-glucuronidase (Assay ID Mm00446953_
m1), hypoxanthine guanine phosphoribosyl transferase 1 (Assay ID Mm00446968_m1), mitochondrial riboso-
mal protein L19 (Assay ID Mm00452754_m1).
Enteroid culture and videomicroscopy. The enteroid culture of isolated crypt epithelium from the jeju-
num has been previously described in detail48. Distal jejunal enteroids were plated in chambered glass microscope 
slides (ThermoFisher) and overlaid with growth medium containing Ham’s F-12 medium with 5% FBS, 50 µg/mL 
gentamicin, 125ng/mL R-spondin1, 25 ng/mL noggin and 12.5 ng/mL epidermal growth factor. Growth medium 
was changed every 3–4 days and enteroids were passaged every 7–10 days. Passages 1–2 were used for experimen-
tation. For videomicroscopy, the microscope slide was fitted with a polycarbonate perfusion chamber (Warner 
Instruments) for superfusion at 37 °C. Single goblet cells were imaged in cross-section using a 60x water immer-
sion objective of an upright Olympus BX-50WI microscope (Olympus). Enteroids were luminally perfused with a 
micropipette for ~5-min before the addition of 100 µM carbachol into the basolateral bath to stimulate exocytosis. 
Images were acquired at 5-sec intervals for ~15 min using a Sensi-Cam digital camera (Cooke) and Slidebook 5.0 
software (Intelligent Imaging Innovations).
Nasal potential difference (NPD) measurements. NPDs were obtained from the nasal lumen in anes-
thetized mice as previously described49,50. The change in NPD (mV) was assessed in response to chloride-free 
HEPES-buffered Ringer’s containing forskolin (10 µM) and amiloride (100 µM).
Identification of hCFTR BAC integration site and copy number. The hCFTR BAC insertion site in 
the mouse was identified using Mate Pair whole genome sequencing on an Illumina HiSeq instrument. The result-
ing data was mapped using CLC Genomics Workbench 8.02 from Qiagen and used to identify junction sequences 
between the transgene sequences and the mouse genome (GRCm38-mm10). In addition, fluorescence in situ 
hybridization (FISH) was completed using a fluorescently labeled BAC on mouse embryonic stem cells created 
from embryos carrying the hCFTR transgene by Cell Line Genetics as previously described51. A single insertion 
site on mouse chromosome 8 was identified in region 8qB2 (58490672 to 58501953). At this single integration 
site, the copy number of hCFTR was estimated using qPCR with 3 sets of primers spread throughout hCFTR as 
previously described52.
Short-circuit current measurement. Freshly excised intestinal sections were stripped of the seromus-
cular layers and mounted on Ussing chambers for the measurement of short-circuit current (Isc) as previously 
described21. The mucosal surfaces were bathed with Krebs bicarbonate Ringers (KBR) containing (in mM): 140.0 
Na+, 5.2 K+, 2.8 PO42−, 115.0 Cl−, 25.0 HCO3−, 1.2 Ca2+, 1.2 Mg2+, 4.8 gluconate−, 10.0 mannitol (apical) or glu-
cose (basolateral) and gassed with 95% O2-5% CO2 at 37 °C (pH 7.4). KBR baths contained 1 µM indomethacin 
(bilateral) and 0.1 µM tetrodotoxin (basolateral). In Cl–free experiments, 115 mM Na+ isethionate− was substi-
tuted equimolar for NaCl. Colonic preparations were pre-treated with 10 µM amiloride to block electrogenic Na+ 
absorption. Following a ~20-min equilibration period, intestinal tissue were treated with a forskolin (10 µM)/ 
3-isobutyl-1-methylxanthine (100 µM, IBMX) cocktail for 20 min before treatment with CFTRinh-172 (10 µM, 
15 min).
Materials. EGF and noggin were obtained from R&D Systems (Minneapolis, MN). Recombinant R-spondin1 
was isolated as described previously53.
equipment and settings. Tissue photomicrographs (H&E stain) - Images acquired using Olympus IMT2 
inverted light microscope (20X objective), an Infinity 1–3 C camera (Lumenera) and Image Pro Plus 6.3 soft-
ware (Media Cybernetics) at pixel dimension = 2048 × 1536, image bit depth = 24 and resolution 300dpi (HxV). 
Images were adjusted equally for brightness and contrast. Goblet cell videomicroscopy – Images were acquired 
using an Olympus BX-50WI upright light microscope (60X objective), a Sensi-Cam camera (Cooke) and 
Slidebook 5.0 software (Intelligent Imaging Innovations) at pixel dimension = 640 × 512, image bit depth = 24 
and resolution = 96dpi (HxV). Images were adjusted for brightness and contrast. Immunoblots – Images were 
acquired using ChemiDoc XRS + System and ImageLab 5.1 software (BioRad) at pixel dimension = 3921 × 2924, 
image bit depth = 24 and resolution = 600dpi (HxV).
Imaging flow cytometry. Lung tissue was isolated from mice and passed through a 70 µm cell strainer. 
Cells were resuspended in 1x PBS with a Complete Protease inhibitor tablet (Roche). Separated cells were kept 
on ice and fixed for 30 minutes with 4% paraformaldehyde at 4 °C. All staining procedures were carried out 
in the presence of 2% BSA in 1x PBS. Assessment and quantification of CFTR were performed using imaging 
flow cytometry with RB7865, a rabbit polyclonal antibody directed towards the first extracellular loop of CFTR 
(Biomatik) (1). Primary anti-CFTR antibody RB7685 was adjusted to the same final protein concentration of 
240 ng/µl, AF488 secondary antibody was prepared at 1:5000 dilution according to the manufacturer’s instruc-
tions54. For each sample, 20000 events were collected on the Amnis Imagestream using Channels 1(Brightfield1), 
2 (AF488), 6 (Sidescatter), 9(Brightfield2) and 11(DRAQ5). The following laser powers were used throughout the 
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experiment, 488 nm = 100 mW, 658 nm = 120 mW and 768 nm = 3.52 mW. The single dye compensation controls 
were collected at the same laser powers to adjust for bleed over between channels. Data processing was carried 
out using IDEAS 6.2. All samples were processed with identical settings, first focused cells were selected and then 
divided into single cells and multiple cells using the Area versus Aspect Ratio discrimination. The single cell pop-
ulation was then further evaluated by the length in the brightfield to identify ciliated cells. To further discriminate 
between dead and live cells the distribution of the nuclear stain versus the CFTR stain was evaluated. Cells with 
co-localization of CFTR and DRAQ5 were considered dead or permeabilized. The remaining cell population was 
then used for quantification and image analysis.
Statistics. Cumulative data are reported as the mean ± SE. Data between two groups were compared using a 
two-tailed unpaired Student t-test or, if not normally distributed with equal variances, by Mann-Whitney Rank 
Sum test. Data from multiple treatment groups were compared using a one-way ANOVA with a post hoc Tukey’s 
t-test. Data from the Isc time course were tested using repeated measures ANOVA with a Dunnet’s t test. The 
non-parametric Kaplan-Meier estimator test was used to determine differences in survival. The Kruskal-Wallis 
test was used to determine differences between cell populations with CFTR antibody staining. A probability value 
of P < 0.05 was considered statistically significant.
Data Availability
The authors will make materials, data and associated protocols promptly available to readers without undue qual-
ifications in material transfer agreements.
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